Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 1 Neuroblastoma 1

Interventions

Cyclophosphamide 34 Etoposide 25 Doxorubicin 20 Carboplatin 20 Vincristine 19 Isotretinoin 19 Topotecan 17 Temozolomide 17 Irinotecan 16 Filgrastim 16 Melphalan 15 Cisplatin 15 sargramostim 14 Radiotherapy 14 Granulocyte-Macrophage Colony-Stimulating Factor 13 3-Iodobenzylguanidine 12 dinutuximab 11 Peripheral Blood Stem Cell Transplantation 11 naxitamab 9 Thiotepa 9 Magnetic Resonance Spectroscopy 9 humanized 3F8 anti-GD2 monoclonal antibody 7 Granulocyte Colony-Stimulating Factor 7 Busulfan 7 X-Rays 6 Specimen Handling 6 Phantoms, Imaging 6 Ifosfamide 6 Antilymphocyte Serum 6 fludarabine phosphate 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neuroblastoma × racotumomab × Clear all

NCT02998983 2023-09-11

Racotumomab in Patients With High-risk Neuroblastoma

Laboratorio Elea Phoenix S.A.

Phase 2 Completed

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡